Badanie anakinra w leczeniu pacjentów z nowotworami mieloproliferacyjnymi opornymi na terapię cytoredukcyjną

Initial visit and baseline assessments

After joining the study you attend the first visit where blood is drawn to measure serum calprotectin (a protein that reflects inflammation) and other laboratory values.

You also complete questionnaires about symptoms such as itching, fever and night sweats, and fill out a baseline quality‑of‑life Questionnaire.

Start of anakinra treatment

You receive Kineret 100 mg in a pre‑filled syringe for subcutaneous injection (the medicine is placed under the skin).

The prescribed dose is 100 mg per injection; the exact frequency follows the study protocol.

Treatment is planned for a period of three months.

Daily self‑administration and diary recording

You inject the medication yourself according to the schedule and record each injection in a patient diary as yes or no.

The diary is kept for the whole three‑month treatment period.

Month‑3 follow‑up visit

After three months you return for a visit where blood is drawn again to measure serum calprotectin and other laboratory parameters.

Questionnaires about symptoms and quality of life are completed again.

The study team evaluates whether there is a decrease in serum calprotectin compared with the baseline value.

Month‑6 follow‑up visit

Six months after the start of the study you attend a second follow‑up visit.

Blood samples are taken for the same laboratory tests as at baseline and month‑3.

Additional questionnaires are completed, and any adverse events that occurred during the study are recorded.